The lancet oncology
-
The lancet oncology · Jul 2022
Multicenter StudyCatastrophic expenditure and treatment delivery outcomes in patients with colorectal cancer in India: a prospective, multicentre cohort study.
Little is known about the factors preventing patients with colorectal cancer in India from receiving the treatment they need to reach the best oncological outcomes. Patients often struggle to pay for cancer care, possibly leading to treatment dropout. The aim of this study was to assess treatment adherence and catastrophic expenditure rates in a cohort of patients with colorectal cancer in India. ⋯ National Institute for Health Research Global Health Research Unit Grant (NIHR 16.136.79) with aid from the UK Government to support global health research.
-
The lancet oncology · Jun 2022
Randomized Controlled Trial Multicenter StudyAdebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor prognosis and treatment options are scarce. Immunotherapy has shown robust clinical activity in ES-SCLC in previous phase 3 trials. We aimed to assess the efficacy and safety of adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, with standard chemotherapy as a first-line treatment for ES-SCLC. ⋯ Jiangsu Hengrui Pharmaceuticals.
-
The lancet oncology · Jun 2022
Multicenter StudyEffect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study.
Awake mapping has been associated with decreased neurological deficits and increased extent of resection in eloquent glioma resections. However, its effect within clinically relevant glioblastoma subgroups remains poorly understood. We aimed to assess the benefit of this technique in subgroups of patients with glioblastomas based on age, preoperative neurological morbidity, and Karnofsky Performance Score (KPS). ⋯ None.
-
The lancet oncology · Jun 2022
Multicenter StudyEZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Treatment options for malignant pleural mesothelioma are scarce. Tazemetostat, a selective oral enhancer of zeste homolog 2 (EZH2) inhibitor, has shown antitumour activity in several haematological cancers and solid tumours. We aimed to evaluate the anti-tumour activity and safety of tazemetostat in patients with measurable relapsed or refractory malignant pleural mesothelioma. ⋯ Epizyme.
-
The lancet oncology · May 2022
Randomized Controlled Trial Multicenter StudySwitch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Anticancer treatment regimens typically cause unpleasant side-effects. We aimed to investigate the benefit of switch maintenance endocrine therapy plus bevacizumab after fixed cycles of first-line induction chemotherapy with weekly paclitaxel plus bevacizumab in patients with oestrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer. ⋯ For the Japanese translation of the abstract see Supplementary Materials section.